Oxecta (oxycodone HCl)

Company
Pfizer

Approval Status
Approved June 2011

Treatment for
acute and chronic moderate to severe pain

Areas
Neurology & Nervous System , Pharmacology

Oxecta is an immediate release tablet formulation of the opioid analgesic oxycodone HCl. This formulation was developed on Acura Pharmaceutical's patented Aversion Technology platform, which is designed to limit or impede opioid abuse via intravenous injection of dissolved tablets and nasal snorting of crushed tablets.

Oxecta is specifically indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

Oxecta is supplied as a tablet that must be swallowed whole; it is not amenable to crushing and dissolution. The dose of Oxecta should be individually adjusted according to severity of pain, and the patient’s response, weight, age, and prior analgesic treatment experience. The recommended starting dose is in the range of 5 to 15 mg every 4 to 6 hours as needed for pain.

FDA Approval
Two phase 1 pharmacokinetic studies demonstrated (a) Oxecta tablets are bioequivalent to the anticipated reference listed drug under fasted conditions, and (b) Oxecta tablets have greater total oxycodone plasma levels with a lower peak drug concentration under fed compared to fasted conditions.

Serious adverse reactions that may be associated with Oxecta include the following:

  • respiratory depression
  • respiratory arrest
  • circulatory depression
  • cardiac arrest
  • hypotension
  • shock

Adverse events associated with the use of Oxecta may include, but are not limited to, the following:

  • nausea
  • constipation
  • vomiting
  • headache
  • pruritus
  • insomnia
  • dizziness
  • asthenia
  • somnolence

Oxecta is an immediate release tablet formulation of the opioid analgesic oxycodone HCl. This pure opioid agonist is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Oxecta was developed on Acura Pharmaceutical's patented Aversion Technology platform, which is designed to limit or impede opioid abuse via intravenous injection of dissolved tablets and nasal snorting of crushed tablets.

For additional information regarding Oxecta or the management of moderate to severe pain, please visit the Pfizer web page.

Oxecta Drug Information

The Oxecta drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top